The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study

Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited. Methods: Ninety-four patients who received pyrotinib as a th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, D. J, Chen, Q. T, Anwar, M., Xie, N., Ouyang, Q. C., Fan, P. Z., Qian, L. Y., Chen, G. N., Zhou, E. X., Guo, L., Gu, X. W., Ding, B. N., Yang, X. H., Liu, L. P., Deng, C., Xiao, Z., Li, J., Wang, Y. Q., Zeng, S., Wang, Shouman, Yi, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428978/
https://www.ncbi.nlm.nih.gov/pubmed/34512325
http://dx.doi.org/10.3389/fphar.2021.682568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428978/
https://www.ncbi.nlm.nih.gov/pubmed/34512325
http://dx.doi.org/10.3389/fphar.2021.682568

Ejemplares similares